OMNITROPE SurePal 45 IU Sandoz Human Growth Hormone

Pharmaceutical Product Overview

OMNITROPE SurePal 45 IU Sandoz Shop in Poland is a prescription medicine containing somatropin, a recombinant form of human growth hormone. The 15 mg/1.5 mL presentation contains 15 mg of somatropin, equivalent to 45 IU, in one cartridge. It is supplied as a clear, colourless solution for injection and is specifically designed for use with the SurePal 15 injection device.

Omnitrope is manufactured and marketed within the Sandoz pharmaceutical organisation and is authorised as a biosimilar medicine. Biosimilar medicines are biological medicines that have been demonstrated to be highly similar to an already authorised reference biological medicine. The European Medicines Agency has assessed Omnitrope under the applicable biosimilar framework.

Active Ingredient – Somatropin

The active substance in Omnitrope is somatropin. Somatropin is a recombinant version of human growth hormone, produced using recombinant DNA technology. Naturally occurring growth hormone is produced by the pituitary gland and plays an important role in childhood growth and development. It also influences the body's metabolism of proteins, fats and carbohydrates.

In the 45 IU presentation, each millilitre contains 10 mg of somatropin, corresponding to 30 IU. The complete 1.5 mL cartridge therefore contains 15 mg of somatropin, equivalent to 45 IU.

SurePal 15 Cartridge System

The Omnitrope 15 mg/1.5 mL presentation is supplied in a cartridge intended specifically for use with SurePal 15. The product information states that this presentation should only be administered using the designated SurePal 15 injection device and appropriate sterile, disposable pen needles. Patients or caregivers should receive suitable instruction from a doctor or qualified healthcare professional before using the device.

The cartridge format provides a ready-to-use solution rather than requiring the user to prepare a powder-and-solvent formulation. The solution should be clear and colorless. If it appears cloudy or contains visible particles, the product should not be used and professional advice should be obtained.

Medical Uses of Omnitrope

Omnitrope is used under medical supervision for specific conditions involving growth hormone deficiency or growth disturbances. According to European product information, approved uses include treatment of children and adolescents with growth disturbance caused by insufficient growth hormone secretion.

It is also indicated in certain children with growth disturbances associated with Turner syndrome, chronic renal insufficiency, or being born small for gestational age when appropriate catch-up growth has not occurred. In selected paediatric patients with Prader-Willi syndrome, Omnitrope may be used to support growth and body composition when the diagnosis has been appropriately confirmed.

For adults, Omnitrope is indicated as replacement therapy for adults with pronounced growth hormone deficiency. Adult growth hormone deficiency may have been present since childhood or may develop later because of an underlying hypothalamic or pituitary condition. Appropriate medical assessment and testing are required before treatment.

How Somatropin Works

Human growth hormone has several physiological functions throughout the body. During childhood and adolescence, growth hormone contributes to normal physical growth. It also participates in processes involving protein metabolism, fat metabolism and carbohydrate metabolism.

Somatropin in Omnitrope Online in Poland is designed to replace or supplement growth hormone when a clinically diagnosed deficiency or an approved growth-related condition requires treatment. The exact treatment plan depends on the patient's diagnosis, age, body characteristics, clinical response, and other medical factors.

Because growth hormone affects several biological systems, treatment requires appropriate medical assessment and ongoing monitoring rather than being considered a general-purpose hormone product.

Biosimilar Status

Omnitrope has an established biosimilar status in the European Union. The EMA describes a biosimilar as a biological medicine that is highly similar to an already authorised reference biological medicine. Omnitrope was developed as a biosimilar to the reference medicine Genotropin.

The EMA reports that Omnitrope was evaluated for comparable quality, safety, and effectiveness in accordance with the regulatory requirements for biosimilar medicines.

This regulatory classification is important when describing the product because biosimilars are evaluated through a specific scientific and regulatory pathway rather than being treated in exactly the same way as conventional small-molecule generic medicines.

Pharmaceutical Form and Composition

OMNITROPE SurePal 45 IU Shop Online Poland is presented as a 15 mg/1.5 mL solution for injection in a cartridge. Each cartridge contains:

• Somatropin: 15 mg, equivalent to 45 IU
• Concentration: 10 mg/mL, equivalent to 30 IU/mL
• Pharmaceutical form: clear, colourless solution for injection
• Delivery system: SurePal 15 cartridge device

The formulation also contains excipients such as disodium hydrogen phosphate heptahydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, poloxamer 188, phenol and water for injections.

Prescription Medicine and Professional Supervision

Omnitrope is a prescription-only medicine. Treatment should be initiated and monitored by a physician experienced in managing patients with growth disorders. The dose is individually determined according to the patient's medical condition and other relevant clinical factors.

Somatropin should not be treated as a general-purpose product for bodybuilding, cosmetic purposes or unsupervised fat-loss programs. Its use should remain within an appropriate medical indication and under qualified professional supervision.

Storage and Handling

Proper storage is an important part of maintaining the quality of a biological medicine. Official product information states that unopened Omnitrope cartridges should be stored and transported under refrigeration at 2°C to 8°C and should not be frozen. The product should remain in its original packaging to protect it from light.

After the cartridge has been opened, the product information specifies a limited in-use period. The official packaging and current patient information should always be checked for the applicable instructions before use.

Patients should also avoid using a cartridge if the solution does not appear clear and colourless. Any questions about storage, handling or product integrity should be directed to a pharmacist or healthcare professional.

Quality, Identification and Authenticity

When reviewing a prescription biological medicine such as Omnitrope, product identification is important. Users should check the medicine name, strength, cartridge presentation, expiry information, packaging integrity and applicable regulatory information.

The official EMA product information identifies Sandoz GmbH as the marketing authorisation holder for Omnitrope in the European Union.

Information from unofficial listings should not replace the approved product information supplied with the medicine. If the packaging, strength, appearance or instructions differ from the information provided by an authorised source, professional verification should be obtained before use.

Safety and Medical Considerations

Like other medicines containing somatropin, Omnitrope has specific contraindications, precautions, interactions and potential adverse effects that need to be considered by healthcare professionals. Somatropin treatment is not appropriate for every patient.

The EMA has emphasised that somatropin-containing medicines should be used appropriately and that treatment requires attention to the approved indications and safety information.

Patients should therefore discuss their medical history, existing conditions, other medicines and treatment objectives with their healthcare professional before starting therapy. Any unusual symptoms or concerns during treatment should be discussed with the treating clinician.

Product Summary

OMNITROPE SurePal 45 IU Sandoz Human Growth Hormone Online Order Poland is a prescription somatropin medicine supplied as a 15 mg/1.5 mL cartridge, equivalent to 45 IU of recombinant human growth hormone. It is specifically designed for use with the SurePal 15 delivery system and is authorised for defined medical indications involving growth hormone deficiency and certain growth disturbances.

Its established biosimilar status, defined pharmaceutical composition, dedicated cartridge system and regulated medical indications make accurate product information particularly important. Treatment should be based on a confirmed medical indication and supervised by an appropriately qualified healthcare professional.

For the most accurate information regarding indications, contraindications, storage, administration and safety, users should consult the current official product information and speak with their doctor or pharmacist.